<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528955</url>
  </required_header>
  <id_info>
    <org_study_id>DIREKHT</org_study_id>
    <nct_id>NCT02528955</nct_id>
  </id_info>
  <brief_title>De-Intensification Radiotherapy Postoperative Head Neck</brief_title>
  <acronym>DIREKHT</acronym>
  <official_title>De-intensification of Postoperative Radiotherapy in Selected Patients With Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Erlangen-Nürnberg Medical School</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Erlangen-Nürnberg Medical School</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In patients with squamous cell carcinoma of the oral cavity, the oropharynx and larynx with&#xD;
      &gt;= pT3 and or pN+ postoperative radio - or radiochemotherapy is the standard of care.&#xD;
      Postoperative radiochemotherapy is indicated in patients with multiple lymph node metastasis,&#xD;
      lymph node metastasis with extracapsular spread and or R1/2 resection.&#xD;
&#xD;
      Locoregional control rates are over 80% after surgery and radio(chemo)therapy. But many&#xD;
      patients suffer from therapy-related long-term side-effects, like xerostomia, dysphagia,&#xD;
      fibrosis, trismus etc.&#xD;
&#xD;
      The aim of this study is to investigate if depending on primary tumor stage, quality of&#xD;
      resection ( resection margin) and number of lymph node metastasis and performed neck&#xD;
      dissection an adapted de-intensified dose- and target volume concept may be performed without&#xD;
      reducing locoregional-control but with reducing radiotherapy-related side-effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is a non-randomized phase-II trial. In total there are 3 therapy arms.&#xD;
&#xD;
      Patients are assigned to one of these therapy arms according to the tumor status and the&#xD;
      quality and kind of surgery. The aim of this study is to investigate if a risk-adapted dose-&#xD;
      and target-volume concept in clearly defined patient groups is possible to individualize&#xD;
      postoperative radiotherapy without reducing locoregional-control but with reducing&#xD;
      radiotherapy-related side-effects.&#xD;
&#xD;
      There are two main issues to investigate:&#xD;
&#xD;
        1. Dose prescription in primary tumor region:&#xD;
&#xD;
           In this study it should be investigated if a dose reduction to 56 Gy in the primary&#xD;
           tumor region is possible, if the resection margin is &gt;= 5mm, tumor stage is &lt;=pT2 and if&#xD;
           there are no other risk factors like perineural spread or peritumoral lymphangiosis.&#xD;
&#xD;
        2. Target volume definition in elective lymph node levels&#xD;
&#xD;
           It should be investigated if ipsilateral cervical lymph irradiation alone allows&#xD;
           adequate locoregional control in selected patients:&#xD;
&#xD;
           ipsilateral lymph node metastasis &lt;=3 and contralateral pN0 (adequate contralateral&#xD;
           selective neck dissection performed) or contralateral cN0 (in patients with strictly&#xD;
           ipsilateral localized tumors of the oral cavity or oropharynx)&#xD;
&#xD;
           Considering these facts 3 therapy groups are possible:&#xD;
&#xD;
           A:&#xD;
&#xD;
           Criteria:&#xD;
&#xD;
             -  pT2, R ≥ 5 mm, L0, Pn0&#xD;
&#xD;
                  -  3 lymph node metastasis or patients with &lt; 3 ipsilateral lymph node metastasis&#xD;
                     and a bilateral primary tumor without adequate contralateral neck dissection&#xD;
&#xD;
           Intervention:&#xD;
&#xD;
             -  Reduction of radiation dose in the primary tumor region to 56 Gy,&#xD;
&#xD;
             -  Elective Radiotherapy of both neck sides&#xD;
&#xD;
           B:&#xD;
&#xD;
           Criteria:&#xD;
&#xD;
           •&gt; pT2 and/or R &lt; 5mm and/or L1 and/or Pn1&#xD;
&#xD;
           •≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (&gt;= 6 resected lymph&#xD;
           nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( &gt;= 5 mm&#xD;
           distance from midline) cancer of the oral cavity or oropharynx&#xD;
&#xD;
           Intervention&#xD;
&#xD;
           •No dose reduction in primary tumor region (prescribed dose in primary tumor region: 64&#xD;
           Gy)&#xD;
&#xD;
           •Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no&#xD;
           contralateral neck irradiation&#xD;
&#xD;
           C:&#xD;
&#xD;
           Criteria&#xD;
&#xD;
             -  pT2, R ≥ 5 mm, L0, Pn0&#xD;
&#xD;
             -  3 ipsilateral lymph node metastasis (and contralateral pN0 (&gt;= 6 resected lymph&#xD;
                nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( &gt;= 5&#xD;
                mm distance from midline) cancer of the oral cavity or oropharynx&#xD;
&#xD;
           Intervention&#xD;
&#xD;
           •Reduction of radiation dose in the primary tumor region to 56 Gy, AND&#xD;
&#xD;
           •Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no&#xD;
           contralateral neck irradiation&#xD;
&#xD;
           In all arms the dose prescription for the lymph node regions is as follows:&#xD;
&#xD;
           •elective lymph node level (either ipsi- or bilateral): 50 Gy&#xD;
&#xD;
           •lymph node level with lymph node metastasis without extracapsular extension: 56Gy&#xD;
&#xD;
             -  lymph node level with lymph node metastasis with extracapsular extension: 64 Gy&#xD;
&#xD;
           In all arms simultaneously chemotherapy is recommended in the following cases:&#xD;
&#xD;
             -  lymph node metastasis with extracapsular extension •&gt;= 3 lymph node metastasis&#xD;
&#xD;
           All patients are stratified according to HPV status.&#xD;
&#xD;
           Additional investigations:&#xD;
&#xD;
             -  swallowing endoscopy (before, 6 and 24 months after radiotherapy)&#xD;
&#xD;
             -  translational research (especially individual radiosensitivity, immunologic&#xD;
                parameters in peripheral blood during treatment)&#xD;
&#xD;
             -  QoL&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>locoregional recurrence rate after 2 years</measure>
    <time_frame>after 2 years</time_frame>
    <description>(recurrence in-radiation field, radiation field margin, outside radiation field for example contralateral)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>after 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival</measure>
    <time_frame>after 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant-metastasis-free survival</measure>
    <time_frame>after 2 and 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute toxicity according to ctc-ae v.4.0</measure>
    <time_frame>during therapy and up to 8 weeks after therapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>late toxicity according to ctc-ae v.4.0</measure>
    <time_frame>follow-up period (5years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life as measured by questionaires</measure>
    <time_frame>before and during treatment and in the follow-up for 5 years</time_frame>
    <description>questionaires: EORTC QLQ-C30 and QLQ-H&amp;N35 and EAT-10</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cancer of Head and Neck</condition>
  <arm_group>
    <arm_group_label>A:De-Intensification Radiotherapy (RT) primary tumor region</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A:De-Intensification Radiotherapy (RT) primary tumor region&#xD;
≤ pT2, R ≥ 5 mm, L0, Pn0&#xD;
&gt; 3 lymph node metastasis or patients with &lt; 3 ipsilateral lymph node metastasis and a bilateral primary tumor without adequate contralateral neck dissection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B:De-Intensification Radiotherapy contralateral lymph nodes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>&gt; pT2 and/or R &lt; 5mm and/or L1 and/or Pn1&#xD;
≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (&gt;= 6 resected lymph nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( &gt;= 5 mm distance from midline) cancer of the oral cavity or oropharynx</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C:De-Intensification RT primary tumor region /contralateral LN</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>≤ pT2, R ≥ 5 mm, L0, Pn0&#xD;
≤ 3 ipsilateral lymph node metastasis (and contralateral pN0 (&gt;= 6 resected lymph nodes) or contralateral cN0 in patients wih strictly ipsilateral localised ( &gt;= 5 mm distance from midline) cancer of the oral cavity or oropharynx</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>A: De-Intensification RT primary tumor region</intervention_name>
    <description>A:&#xD;
Reduction of radiation dose in the primary tumor region to 56 Gy,&#xD;
Elective Radiotherapy of both neck sides</description>
    <arm_group_label>A:De-Intensification Radiotherapy (RT) primary tumor region</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>B: De-Intensification RT contralateral lymph nodes</intervention_name>
    <description>B:&#xD;
No dose reduction in primary tumor region (prescribed dose in primary tumor region: 64 Gy)&#xD;
Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation</description>
    <arm_group_label>B:De-Intensification Radiotherapy contralateral lymph nodes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>C. De-Intensification RT primary tumor region AND contralateral lymph nodes</intervention_name>
    <description>C:&#xD;
Reduction of radiation dose in the primary tumor region to 56 Gy, AND&#xD;
Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation</description>
    <arm_group_label>C:De-Intensification RT primary tumor region /contralateral LN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologic proven squamous cell carcinoma of the oral cavity/larynx/oro- or&#xD;
             hypopharynx&#xD;
&#xD;
          2. Postoperative tumor status:&#xD;
&#xD;
               -  Oral cavity, oropharynx or larynx: pT1-3, pN0-pN2b&#xD;
&#xD;
               -  Hypopharynx: pT1-2; pN1&#xD;
&#xD;
          3. Patients that fulfill one or both of the following criteria:&#xD;
&#xD;
               -  ≤ pT2, R ≥ 5 mm, L0, Pn0&#xD;
&#xD;
               -  ≤ 3 ipsilateral lymph node metastases (if a contralateral adequate neck&#xD;
                  dissection is performed, no contralateral neck dissection is recommended in&#xD;
                  patients with strictly ipsilateral localised tumors of the oropharynx or oral&#xD;
                  cavity)&#xD;
&#xD;
          4. R0-Resection (resection margin ≥ 1mm)&#xD;
&#xD;
          5. No distant metastasis cM0&#xD;
&#xD;
          6. age ≥ 18 years, no upper age limit&#xD;
&#xD;
          7. ECOG ≤ 2&#xD;
&#xD;
          8. Patients that understood protocol contents and are able to behave according to&#xD;
             protocol&#xD;
&#xD;
          9. Signed study-specific consent form prior to therapy&#xD;
&#xD;
         10. In case of indicated simultaneous chemotherapy:&#xD;
&#xD;
               -  adequate bone marrow function (leucocytes &gt; 3,5x10^3, platelets &gt; 100x 10^3,&#xD;
                  hemoglobin &gt; 10g/dl&#xD;
&#xD;
               -  sufficient liver function: bilirubin &lt; 2,0mg/dl, ALT, AST &lt; less than 3 times&#xD;
                  upper limit of normal&#xD;
&#xD;
               -  sufficient renal function: normal serum creatinine, glomerular filtration rate &gt;&#xD;
                  60ml/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. pregnant or lactating/nursing women&#xD;
&#xD;
          2. fertile patients that are not willing to use highly effective methods of contraception&#xD;
             (per institutional standards) during treatment&#xD;
&#xD;
          3. Any condition potentially hampering compliance with the study protocol and follow-up&#xD;
             schedule&#xD;
&#xD;
          4. On-treatment participation on other trials&#xD;
&#xD;
          5. R1 or R2 resection status&#xD;
&#xD;
          6. pN2c and pN3&#xD;
&#xD;
          7. cM1&#xD;
&#xD;
          8. prior radiotherapy in the head and neck region , prior chemo- or immunotherapy&#xD;
             (neoadjuvant/induction)&#xD;
&#xD;
          9. time between surgery and beginning of radio(chemo)therapy &gt; 6 weeks&#xD;
&#xD;
         10. Prior (&gt; 4 months before beginning of radio(chemo)therapy) neck dissection&#xD;
&#xD;
         11. In case of indicated simultaneous chemotherapy:&#xD;
&#xD;
               -  reduced hearing ability (especially upper frequency range)&#xD;
&#xD;
               -  known dihydropyrimidindehydrogenase (DPD) deficiency&#xD;
&#xD;
               -  simultaneous therapy with brivudin or other DPD-inhibitors&#xD;
&#xD;
               -  uncontrolled serious disease, including physical and mental diseases, for example&#xD;
                  within last 6 months:instable angina pectoris, heart attack, serious cardiac&#xD;
                  dysrhythmias, stroke, serious carotid stenosis, neurologic or psychiatric&#xD;
                  disorders including epilepsy, dementia, psychosis; uncontrolled infection; liver&#xD;
                  cirrhosis Child B or C, severe hepatic impairment; severe blood count changes;&#xD;
                  severe renal impairment, HIV&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rainer Fietkau</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Radiooncology, University Hospital Erlangen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marlen Haderlein</last_name>
    <phone>004991318533996</phone>
    <email>marlen.haderlein@uk-erlangen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept. of Radiooncology, University Hospital</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <study_first_submitted>August 10, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <last_update_submitted>August 18, 2015</last_update_submitted>
  <last_update_submitted_qc>August 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and neck cancer</keyword>
  <keyword>postoperative</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>de-intensification</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

